Почетна › Метастатски карцином › Kalifornija › San Francisco
Kliničke studije za Метастатски карцином u gradu San Francisco, CA
25 studija za Метастатски карцином traži učesnike na lokacijama u gradu San Francisco i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Тражи се учесникФаза 3
- Kaiser Permanente, San Francisco
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Тражи се учесникФаза 1/2
- University of California, San Francisco (UCSF), San Francisco
Intratumoral N17350 in Advanced Solid Tumors
Тражи се учесникФаза 1/2
- University of California, San Francisco, San Francisco
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Тражи се учесникФаза 1
- University of California San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Тражи се учесникФаза 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Тражи се учесникФаза 1
- UCSF Medical Center at Mount Zion, San Francisco
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Тражи се учесникФаза 1/2
- UCSF Medical Center at Mission Bay ( Site 0034), San Francisco
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Тражи се учесникФаза 3
- UCSF at China Basin, San Francisco
- UCSF at Mount Zion, San Francisco
- UCSF at Parnassus, San Francisco
- и још 1
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Тражи се учесникФаза 3
- UCSF Medical Center at Mission Bay, San Francisco
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Тражи се учесникФаза 1/2
- Avenzo Therapeutics Recruiting Site, San Francisco
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Тражи се учесникФаза 1/2
- University of California San Francisco, San Francisco
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Тражи се учесникФаза 1
- University of California San Francisco, San Francisco
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Тражи се учесникФаза 2
- University of California, San Francisco, San Francisco
Imaging of Solid Tumors Using 18F-TRX
Тражи се учесникФаза 1
- University of California, San Francisco, San Francisco
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Exelixis Clinical Site #5, San Francisco
Imaging of Solid Tumors Using FAP-2286
Тражи се учесникФаза 1
- University of California, San Francisco, San Francisco
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Тражи се учесникФаза 1
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Тражи се учесникФаза 1/2
- University of California San Francisco (UCSF), San Francisco
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Тражи се учесникФаза 2/3
- University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Тражи се учесникФаза 1
- University of California San Francisco-Benioff Children's Hospital, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Тражи се учесникФаза 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
Тражи се учесникФаза 1
- University of California, San Francisco, San Francisco
Studije za Метастатски карцином u drugim gradovima
- Houston, TX100 студија
- New York City, NY93 студија
- Nashville, TN69 студија
- Boston, MA61 студија
- Los Angeles, CA57 студија
- Arlington, VA52 студија
- St. Louis, MO52 студија
- San Antonio, TX44 студија
- Washington, DC44 студија
- Dallas, TX44 студија
- Philadelphia, PA42 студија
- Chicago, IL42 студија
Ostale studije u gradu San Francisco
- Рак простате44 студија
- Рак дојке40 студија
- Рак (све врсте)38 студија
- Немалоклетни карцином плућа37 студија
- Затајење срца29 студија
- Рак плућа23 студија
- Меланом21 студија
- Рак јајника20 студија
- Кардиоваскуларне болести20 студија
- Рак панкреаса19 студија
- Глиобластом19 студија
- Колоректални карцином19 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.